Eleven members
The consortium brings together academic groups and industry, including four small and medium sized enterprises.
TARKINAID work organisation
How the preclinical programme is organised
Selection, profiling, safety, disease models
The project is built around a preclinical core, prepared by assay work and compound selection, and delivered by a consortium of eleven members in six countries.
step 01
Compound selection
step 02
In vitro profiling
step 03
Safety and pharmacokinetics
step 04
Disease model validation
The core part of the project is the preclinical analysis of novel Src family kinase inhibitors in various animal models of chronic autoimmune and inflammatory diseases. That core is supported and preceded by a series of in vitro and additional initial in vivo assays, which predict and optimise the most promising inhibitors and test their safety and pharmacokinetic characteristics.
This arrangement keeps compound selection and optimisation ahead of the disease model work, so that resources are concentrated on inhibitors with a plausible safety and pharmacokinetic profile.
Consortium composition
Six countries
To develop a network between European and Brazilian immunologists, two group leaders are from Brazil.
Hungarian coordination
To promote research in Eastern European countries, the coordinator and one small firm are from Hungary.
The coordinator is Dr. Attila Mocsai at Semmelweis University in Budapest. The full beneficiary list is held in the project brochure and summarised on the consortium page.
Experience within the consortium covers the development of small molecule kinase inhibitors, inflammation related in vitro functional studies on leukocytes, and the analysis of in vivo inflammatory disease models in experimental animals. That combination is what the work organisation depends on.
Read next
The four objectives explain what the sequence is for. The publications page explains where output from the programme is indexed.